BIO-Europe

Once limited to decongestants, nasal drug delivery is emerging as one of medicine’s most promising frontiers, offering faster uptake, stronger immunity, and the potential to block transmission before disease takes hold.

The company has secured two major hospital contracts in Sweden and France, with a combined value of approximately SEK 16 million.

The company is strengthening its focus on new partnerships through the appointment of Raheleh Nassaji as Senior Vice President Business Development.

SOPHiA Genetics has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. 

AlzeCure Pharma has entered into a collaboration and out-licensing agreement with the pharmaceutical company Eli Lilly and Company regarding the global rights to the Alzheimer’s project Alzstatin ACD680.

Johnson & Johnson has announced it has entered into a definitive agreement to acquire Firefly Bio, biotech company advancing its Firelink degrader antibody conjugate (DAC) platform, for USD 1 billion in cash.

It’s no small irony that one of the world’s most effective cancer drugs also is one of the least accessible.